Back Human Papillomavirus (HPV)

Human Papillomavirus (HPV)

Electrocautery Prevents Progression to Anal Cancer in HIV Positive and Negative Gay Men

Electrocautery ablation to remove abnormal tissue significantly reduced the likelihood of progression to anal cancer for both HIV positive and HIV negative gay men with high-grade anal intraepithelial neoplasia, according to a study described in the November 30, 2011, advance online edition of the Journal of Acquired Immune Deficiency Syndromes.alt

Read more:

AASLD 2011: High Rate of Cancer-Causing HPV among Women with Hepatitis C Awaiting Liver Transplants

Nearly 1 in 5 women undergoing liver transplantation -- most of them due to chronic hepatitis C virus (HCV) infection -- were also infected with cancer-causing types of human papillomavirus (HPV), even though their behavioral risk was low, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco. alt

Read more:

ICAAC 2011: HPV Testing and Pap Smears Identify Anal Cancer Risk in HIV+ Men

Human papillomavirus (HPV) testing and anal Pap testing can detect abnormal cell changes that could progress to anal cancer in HIV positive gay men at an earlier and more treatable stage, and is likely to be cost-effective, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this month in Chicago.  alt

Read more:

Rising Rate of Mouth and Throat Cancers Caused by HPV

Oral cancers caused by oncogenic human papillomavirus (HPV) -- the same virus that causes cervical and anal cancer -- are increasing in prevalence, researchers reported in the October 3, 2011, advance online edition of the Journal of Clinical Oncology. The trend may be related to growing acceptance of oral sex and a decline in smoking, and suggests that young men as well as young women could benefit from routine HPV vaccination.alt

Read more:

Two HPV Vaccine Doses May Protect as Well as Three

The bivalent Cervarix human papillomavirus (HPV) vaccine may protect against cervical cancer with 2 doses, which would reduce inconvenience and cost compared with the current standard 3-dose regimen, according to study findings described in the September 9, 2011, advance online edition of the Journal of the National Cancer Institute.alt

Read more: